A single center study:An analysis of the safety and validity of delaying repeated biopsy for patients with atypical small acinar proliferation

VernacularTitle:前列腺不典型小腺泡增生患者推迟重复活检安全性分析的单中心研究
Author: Wen-Tong JI ¹ ; De-Chuan LIU ; Wan-Li CUI ; Yu HU ; Yao WANG ; Jiu-Feng TAN
Author Information

1. 吉林大学中日联谊医院,泌尿外科二病区,吉林长春 130032
Keywords: atypical small acinar proliferation; prostate biopsy; prostate cancer
From: National Journal of Andrology 2023;29(5):414-419
CountryChina
Language:Chinese
Abstract: Objective:To explore the association between atypical small acinar proliferation(ASAP)and subsequent diagnosis of intermediate and high risk prostate cancer(PCa),and analyze whether delaying repeat biopsy timing is safe and effective.Meth-ods:From June 2000 to June 2022,we retrospectively analyzed the clinical data of 276 patients accepting prostatic biopsy and diag-nosed with ASAP in China-Japan Union Hospital of Jilin University.54.7％(151/276)patients had a repeat biopsy.We used statis-tic methods to process the data.Results:25.2％(38/151)patients were diagnosed with PCa on repeat biopsy.Among them,78.9％(30/38)patients had Gleason score(GS)3+3 and 21.1％(8/38)had GS 3+4 disease.There were 4 and 6 patients got RP re-spectively in the two cohorts.Only 5.3％(8/151)of ASAP patients were diagnosed as intermediate risk PCa in repeated biopsy and specially,no high risk PCa was identified in our study.Conclusion:It was safe and valid to delay the repeat biopsy.